I find the article below very interesting for two reasons. First, I wholeheartedly agree with #Biocon's CEO that launching an #adalimumab#biosimilar isn't about dominating that particular market, but about getting a piece of the pie, because "It’s a very large opportunity, and even a small market share is a large value.” In the event all (or most) of the ABs launched in the US and market share was distributed evenly, they each could be billion-dollar drugs (even when accounting for market share loss to other products, such as #Skyrizi and #Rinvoq). The second interesting piece is their marketing plan based on their dual-pricing strategy. High-list/high-rebate may be more attractive to payers, while a low-list price is more for organizations involved with GPOs. However, I'm still uncertain on which pricing strategy will benefit the patients, and overall drug spending, more.
Christopher MillerShaila Yoshidahttps://lnkd.in/ey4W4BwD
Well that was unexpected. After only 7 months at this job, I’m joining the ranks of those that are #opentowork.
It’s a long post and I’d be grateful if you could read and forward this along?
Some personal thoughts after only 7 months at Inspire and why I know that getting laid off has nothing to do with my abilities and my performance.
Here are just 2 examples of what I achieved through research and design:
Integrate UX Research into the product development process. I re-designed the information architecture of the iOS app and the interaction design of key user flows. Not only did I test the early versions of the designs with actual users, I took the results and improved upon the experience just in time for it to go into the development cycle having a certain level of confidence that we were moving in the right direction.
In another instance, I ran a series of usability tests on a web app prototype and one of the tasks I asked participants to do, all participants found to be confusing.The information architecture of this one section of the prototype didn’t make sense to participants. Based on this, I made a change to the information architecture and how the content was labeled. Talk about saving time and money before the thing was actually built and released out into the world!
I do both research and design. I love the craft of UX Design (ux research/testing, information architecture, interaction design, visual design) Not only that, I’m really good at integrating myself into the product development process and being part of a TEAM to build something that achieves meaningful outcomes.
I love working on problems in the Healthcare UX space. And it turns out, I’m actually good at it. I’m a workhorse: getting into the minds and behaviors of users AND going from high-level user flows, to grayscale sketches/wireframes all the way to high-fidelity UI is my jam.
I also love to mentor and lead fellow UX’ers and pushing them to improve in this craft, connect them to amazing opportunities and to be the best version of themselves.
And what I’ve learned over my decades of experience, is that all this work I do has never been about me. It’s about the people (patients, clinicians) and helping them do what they need to do and making things really really easy for them.
I’m hoping the LinkedIn network can help guide me to the next adventure. Not only will you get someone who is passionate about UX Design and Research, you’ll get someone who deeply believes in these operating principles:
-Positivity
-Humility (I like to listen first)
-Kindness, respect and love (yes, I said love!)
-Every human I interact with has immeasurable value
-Assume positive intent
-Servant leadership
-Psychological safety
I’m grateful that key leaders Jennifer Moyer, Steph Feller, Rebecca Traish can be references for me and can attest to the work I accomplished (and how I did it!) in my brief tenure at Inspire.
Let’s get to work!
A bi-annual #PrEP option, that's showing 100% effectiveness, is very exciting for #hivprevention. #Lenacapavir will provide an important new option for patients who struggle with adherence or side effects of the oral options, and will reduce the dosing interval, compared with #Apretude, by two-thirds. Concerns will always be cost/coverage, especially when #generic#truvada is very inexpensive and preferred with many payers. Additionally, since this will be a medical benefit product like Apretude, what will patient cost sharing look like? Will the office visit copay alone cover it, or will there be an additional cost?
Christopher Millerhttps://lnkd.in/e3ttKegG
Hey everyone! I’m on the lookout for a new role and would really appreciate your support. I’d love to connect with you to tell you more about my experience, and catch up on what’s been happening with you.
If you hear of any exciting opportunities or are open to chatting, send me a message or comment below! Thanks so much!
#OpenToWork
"Keep the long view in mind—the final objective—the things that matter most when it’s all said and done."
This weekend, West Point's graduating class will commission as second lieutenants, joining thousands of others from ROTC programs around the United States as the Army's newest leaders. Here's some advice as they begin their careers from a former commanding general of US Special Operations Command.
Interesting to see #subcutaenous#ocrevus making progress towards market entry. With an #EMA decision in the near future, could the #US be far behind? Also, once it is approved, what will happen to #Kesimpta, #Briumvi, and even IV Ocrevus? IV Ocrevus is already approved for home infusion, so 10 minutes (q6months) in a patient's home for the SQ version could really raise the profile (with #multiplesclerosis#patients) for an already successful therapy.
https://lnkd.in/eJ7qH3ZS
In my previous role, I'd done a lot of #multiplesclerosis market research featuring #healthplans, #PBMs, #healthsystems, #medicalgroups, and #neurologists, but I've always been curious about the #patient perspective. For example, when a new therapy is launched (or in development), how might it affect a patient's prognosis? Or, when a payer's access policy changes, what does that mean for the patient? Ben Hofmeister's articles may not get directly into those specific issues, but they give a lot of insight into the MS patient experience. As he points out in the article below, "If you know one person with MS, then you know one person with MS," which is further highlighted when considering the needs of #relapsing vs. #progressive MS patients.
https://lnkd.in/ew_CmewM
An interesting article that points out the potential of using #AI in #drugdevelopment. The promise seems to largely be in discovery and preclinical development, yet such claims come from companies using the tech. "Until they can be independently verified, some caution is in order." Still, with discovery-to-marketing authorization timelines of 12+ years, and costs close to $3bn, my interest is piqued.
While not quite on #Humira's level, #Stelara's power will start to *slowly* slip following upcoming biosimilar launches (ie, Uzpruvo [EU] in July and Wezlana [US] next January). It will be interesting to see what pricing looks like to really get a handle on how quickly the slide will be. #johnsonandjohnsonChristopher